FINWIRES · TerminalLIVE
FINWIRES

Aurobindo Pharma Gets US FDA's Voluntary Action Indicated Classification for Telangana, India Unit; Shares Up 3%

By

-- Aurobindo Pharma (NSE:AUROPHARMA, BOM:524804) has received a "voluntary action indicated" from the US Food and Drug Administration (US FDA) after the inspection of its oral solid dosage manufacturing unit in the Mahaboobnagar district of Telangana, India.

The inspection, which was conducted between Jan. 28 and Feb. 10, resulted in the US FDA issuing a 'Form 483' with nine observations, according to a Wednesday filing to the Indian stock exchanges.

With this classification, the inspection is now closed.

The company's shares were up over 3% in recent trade.

Related Articles

Asia

Rundu Pharmaceutical Gets Nod to Market Losartan Potassium

Zhuhai Rundu Pharmaceutical (SHE:002923) obtained approval from China's National Medical Products Administration for the marketing of losartan potassium, according to a Shenzhen bourse filing on Wednesday.The drug is used for the treatment of primary hypertension and chronic heart failure.The pharmaceutical company's shares rose by less than 2% at the close.

$SHE:002923
International

Final PMI: UK Private Sector Growth Accelerates in April

Britain's private sector output growth increased in April, indicating a moderate rise in manufacturing production and in services sector activity, data from S&P Global showed.The seasonally adjusted S&P Global UK PMI Composite Output Index rose to 52.6 from 50.3 in March, according to final data published Wednesday. The flash estimate stood at 52.Meanwhile, the services PMI came in at 52.7, compared with the previous month's 50.5 and the preliminary reading of 52.

$^FTSE
Australia

Versigent Q1 Net Income Falls, Sales Rise

Versigent (VGNT) reported Q1 net income Tuesday of $81 million, down from $96 million a year earlier.Net sales for the quarter ended March 31 were $2.21 billion, up from $2.02 billion a year earlier.Analysts surveyed by FactSet expected $2.09 billion.The company said it expects 2026 revenue of $9.10 billion to $9.40 billion. Analysts surveyed by FactSet expect $9.25 billion.Shares of the company traded more than 5% higher in recent premarket activity Wednesday.Price: $39.39, Change: $+1.89, Percent Change: +5.04%

$VGNT